Technology ID
TAB-4588

PET Imaging of lntegrin Expression with Suitably Labeled RGD Peptides for Multiple Diagnostic Purposes

E-Numbers
E-250-2015-0
Lead Inventor
Chen, Xiaoyuan (shawn) (NIBIB)
Co-Inventors
Lang, Lixin (NIBIB)
NIU, Gang (NIBIB)
Applications
Research Materials
Diagnostics
Therapeutic Areas
Neurology
Immunology
Cardiology
Development Stages
Pre-Investigational Device Exemption
Research Products
Research Equipment
Lead IC
NIBIB
ICs
NIBIB

This technology includes a number of dimeric RGD peptides which been developed and labeled with various PET isotopes (1BF, 68Ga, and 64Cu) for imaging integrin expression in cancer, inflammation, rheumatoid arthritis, myocardial infarct, stroke and traumatic injury. A number of these peptides have been translated into clinic for diagnosis and therapy response monitoring.

Commercial Applications
A kit formulation for PET radiolabeling.

Competitive Advantages
These dimeric RGD peptides which have been tested in human are the only ones reported that used polyvalency principle; all other RGD peptides developed by industry and academic institutes used only monomeric RGD peptides that do not have as high binding affinity and proper pharmacokinetics as the ones described here.

Request More Info

Licensing Contact:
Shmilovich, Michael
shmilovm@nih.gov

Publications

Collaborations

  • Licensing

Collaboration Description

  • We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology.
Date Published